The licensing deal could set the US drugmaker to vie with Eli Lilly & Co. and Novo Nordisk A/S, the current leaders in a ...

AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the ...

The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.

AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire rights to a long-acting amylin ...

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...

GUB014295 is a subcutaneously administered long-acting amylin agonist that also stimulates calcitonin receptors, according to ...

AbbVie (ABBV) and Gubra announced a license agreement to develop GUB014295, a long-acting amylin analog for the treatment of obesity. Under the ...

AbbVie (NYSE: ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, today ...

Over the past year, many AbbVie Inc. insiders sold a significant stake in the company which may have piqued investors' ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the ...

AbbVie (NYSE:ABBV) has entered into a license deal with Danish biotech Gubra A/S to develop the latter’s experimental obesity ...

Under the leadership of Rob Michael, AbbVie continues to make tremendous progress in developing its immunology and ...